drugset / Trial / NCT07203287
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Timeline
- Start
- 2025-08-26
- Primary completion
- 2026-12-31
- Completion
- 2027-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisatracurium | Small molecule | — | — |
| Comparator | Neostigmine | Other / unclassified | — | — |
| Comparator | Rocuronium | Other / unclassified | — | — |
| Comparator | Sugammadex | Other / unclassified | — | — |
Indications
No indication recorded.